The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated significant profits, the end of its intellectual property protection opened the door to generic competitors, dramatically reducing market share. This presents a particular dilemma for drug manufacturers relying on relat

The story of Viagra, and its creator copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in sales , its website patent expiration created a wave of lower-priced alternatives , significantly eroding its position . While some firms may try to capitalize on male sexual dysfunction, the current land